ALLN-346

DRUG4 trials

Sponsors

Allena Pharmaceuticals

Conditions

Chronic Kidney DiseasesGoutHyperuricemia

Phase 1

ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers

CompletedNCT04236219

Allena PharmaceuticalsHyperuricemia

Start: 2020-09-02End: 2020-11-06Updated: 2021-07-23

Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)

CompletedNCT04829435

Allena PharmaceuticalsGout, Hyperuricemia

Start: 2021-04-21End: 2021-06-01Updated: 2021-07-01

Phase 2

An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)

CompletedNCT04987242

Allena PharmaceuticalsChronic Kidney Diseases, Gout, Hyperuricemia

Start: 2021-07-16End: 2022-03-02Updated: 2023-06-22

Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

TerminatedNCT04987294

Allena PharmaceuticalsChronic Kidney Diseases, Gout, Hyperuricemia

Start: 2022-09-02End: 2022-09-02Updated: 2023-06-23